Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder

Regeneron Pharmaceuticals will share in development of Tessera Therapeutics’ TSRA-196, a Phase 1-ready gene-editing therapy for alpha-1 antitrypsin deficiency (AATD). Other companies developing genetic medicines for this rare disease include Beam Therapeutics, Wave Life Sciences, Korro Bio, and AIRNA. The post Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver &…

Read More

Listen to the Latest ‘KFF Health News Minute’

Jan. 8 Zach Dyer reads the week’s news: Instead of extending extra Affordable Care Act subsidies that would keep monthly premiums more affordable, some Republicans are pushing health savings accounts. Plus, people seeking cheaper health insurance options outside the ACA marketplaces may find some, but they come with downsides.  Jan. 1 Katheryn Houghton reads the week’s news: AI voices can help patients who have had their…

Read More

Rethinking Security Among the Healthcare Workforce Crisis

As hospitals adapt to a landscape marked by staffing shortages, financial pressure and escalating safety concerns, security can no longer operate as an afterthought or a cost center. It must be a strategic enabler that protects the workforce, which in turn protects everyone else. The post Rethinking Security Among the Healthcare Workforce Crisis appeared first…

Read More